EBITDA: Income before interest, taxes, depreciation and amortization.
MiNK Therapeutics, Inc. (INKT) had EBITDA of $-3.18M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-3.13M |
|
-- |
|
-- |
|
$3.22M |
|
$-3.22M |
|
$0.09M |
|
$-3.13M |
|
$-3.13M |
|
$-3.13M |
|
$-3.13M |
|
$-3.13M |
|
$-3.13M |
|
$-3.22M |
|
|
EBITDA |
$-3.18M |
5.02M |
|
5.02M |
|
$-0.62 |
|
$-0.62 |
|
| Balance Sheet Financials | |
$9.30M |
|
$0.32M |
|
$0.32M |
|
$9.62M |
|
$7.57M |
|
-- |
|
$16.07M |
|
$23.64M |
|
$-14.03M |
|
$-14.03M |
|
$-14.03M |
|
5.10M |
|
| Cash Flow Statement Financials | |
$-3.82M |
|
-- |
|
$-0.73M |
|
$13.36M |
|
$8.81M |
|
$-4.55M |
|
$1.05M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.23 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.82M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
22.30% |
|
22.30% |
|
-32.53% |
|
22.30% |
|
$-2.75 |
|
$-0.76 |
|
$-0.76 |
|